1. Home
  2. ACV vs KROS Comparison

ACV vs KROS Comparison

Compare ACV & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virtus Diversified Income & Convertible Fund of Beneficial Interest

ACV

Virtus Diversified Income & Convertible Fund of Beneficial Interest

SELL

Current Price

$23.70

Market Cap

252.4M

Sector

Finance

ML Signal

SELL

Logo Keros Therapeutics Inc.

KROS

Keros Therapeutics Inc.

SELL

Current Price

$10.77

Market Cap

222.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ACV
KROS
Founded
2015
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
252.4M
222.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ACV
KROS
Price
$23.70
$10.77
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
★ $19.83
AVG Volume (30 Days)
31.7K
★ 169.6K
Earning Date
01-01-0001
11-04-2026
Dividend Yield
★ 9.20%
N/A
EPS Growth
N/A
★ 146.00
EPS
★ N/A
N/A
Revenue
N/A
★ $243,864,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.54
$9.69
52 Week High
$29.04
$22.55

Technical Indicators

Market Signals
Indicator
ACV
KROS
Relative Strength Index (RSI) 35.57 42.58
Support Level N/A $10.65
Resistance Level $28.24 $11.86
Average True Range (ATR) 0.63 0.50
MACD -0.00 -0.08
Stochastic Oscillator 5.24 6.92

Price Performance

Historical Comparison
ACV
KROS

About ACV Virtus Diversified Income & Convertible Fund of Beneficial Interest

Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. It invests in a diversified portfolio of convertible securities, income-producing equity securities, and income-producing debt and other instruments of varying maturities, of which a majority of the managed assets are invested in convertibles.

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Share on Social Networks: